Skip to content
Subscriber Only

Plastic Cap Is Crux of Mylan Argument Against Teva’s EpiPen

  • Company argued that different design could confuse patients
  • Teva has attempted to get approval for substitutable generic
Photographer: Daniel Acker/Bloomberg
Updated on

The lack of a cheaper version of Mylan NV’s EpiPen shot may come down to a dispute between drugmakers over a plastic cap.

Unlike Mylan’s one-cap EpiPen, Teva Pharmaceutical Industries Ltd.’s proposed substitutable generic version has two caps, including a removable one that covers the spot where its needle extends. In a petition to the U.S. Food and Drug Administration, Mylan cited that difference as the key reason the agency should reject Teva’s generic -- which is exactly what happened in February of this year.